{"name":"MerLion Pharmaceuticals GmbH","slug":"merlion-pharmaceuticals-gmbh","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Finafloxacin i.v. solution 200 mg","genericName":"Finafloxacin i.v. solution 200 mg","slug":"finafloxacin-i-v-solution-200-mg","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Finafloxacin i.v. solution 200 mg","genericName":"Finafloxacin i.v. solution 200 mg","slug":"finafloxacin-i-v-solution-200-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxOeVJ6bm1lZDYtUWliNDNsSGxWbGUwUjZiLXRNWmV2eUViQk41ZzlxVThzaDBuSFdidlB4R2xhQU16aW96TDdIS1BEckZiaWJXemVQTGUxUmlvVl9wZlJ2UjJCYjNsWnpiRHd0OEt0c2tWREs3UVF2dmtmZUN2S0hoY25LNFhHZ08xNzFWSnVxODFuNlA0N0l3Z29NQ2U1NEpxakpZNmlIYjhXX25aWUlfZzlGX2pSQkNXdlk5N2JqUnFzSXBBMnM0TUJLWFExZ2ZWSG9pMXBGUzJpVGoxTmZ4aV9vckdzWXhTWXhJOE1TM1ltVjhhYXI2V2dCcEI?oc=5","date":"2024-12-11","type":"pipeline","source":"businesswire.com","summary":"Fonseca Biosciences Secures Exclusive US Rights to XTORO - businesswire.com","headline":"Fonseca Biosciences Secures Exclusive US Rights to XTORO","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}